Speciality
Spotlight

       




 


Medicine


   

 




Antibiotics
– MRSA

  

  • Kathryn
    Senior

    FDA
    approves first drug in new class of antibiotics

    The
    Lancet 2000;
    29 April, 355: 1523.

     

    One
    of the problems of drug resistant bacterial
    infections is MRSA (Methicillin Resistant
    Staphylococcus Aureus) which has become a most
    dangerous infection.
    This bacteria has now become Vancomycin-resistant.

     

    A
    new class of antibiotic has now been approved.
    The antibiotic named Zyvox (Linezolid) has
    novel mode of action, it blocks bacterial protein
    production by disrupting the binding of bacterial
    ribosome. It
    is hoped that this will make the treatment of MRSA
    infection simpler.

        

  • Mathew N Lowe and Harriet M Lamb (Auckland,New Zealand)

    Meropenem – An Updated Review of its Use in the Management of Intra-Abdominal Infections.

    Drugs Sept.2000; 60(3): 619-646

      

    Meropenem is a carbapenem antibacterial agent with a broad spectrum of activity which encompasses Gram-negative, Gram-positive and anaerobic bacteria. Like other carbapenems, meropenem is stable against chromosomal and extended-spectrum b-lactamases.



    In patients with moderate to severe intra-abdominal infections, empirical monotherapy with meropenem achieved clinical response rates ranging from 91 to 100% in 7 randomized comparative trials.

       

 



 

           

Speciality Spotlight

       

 
Medicine
   

 

Antibiotics – MRSA
  

  • Kathryn Senior
    FDA approves first drug in new class of antibiotics
    The Lancet 2000; 29 April, 355: 1523.
     
    One of the problems of drug resistant bacterial infections is MRSA (Methicillin Resistant Staphylococcus Aureus) which has become a most dangerous infection. This bacteria has now become Vancomycin-resistant.
     
    A new class of antibiotic has now been approved. The antibiotic named Zyvox (Linezolid) has novel mode of action, it blocks bacterial protein production by disrupting the binding of bacterial ribosome. It is hoped that this will make the treatment of MRSA infection simpler.
        

  • Mathew N Lowe and Harriet M Lamb (Auckland,New Zealand)
    Meropenem – An Updated Review of its Use in the Management of Intra-Abdominal Infections.
    Drugs Sept.2000; 60(3): 619-646
      
    Meropenem is a carbapenem antibacterial agent with a broad spectrum of activity which encompasses Gram-negative, Gram-positive and anaerobic bacteria. Like other carbapenems, meropenem is stable against chromosomal and extended-spectrum b-lactamases.

    In patients with moderate to severe intra-abdominal infections, empirical monotherapy with meropenem achieved clinical response rates ranging from 91 to 100% in 7 randomized comparative trials.
       

 

 

By |2022-07-20T16:41:27+00:00July 20, 2022|Uncategorized|Comments Off on Antibiotics – MRSA

About the Author: